$TOVX
Theriva Biologics, Inc.

2021 Q4 Form 10-K Financial Statement

#000141057822000405 Filed on March 16, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.486M $6.474M $1.153M
YoY Change 115.61% 28.73% -10.13%
% of Gross Profit
Research & Development $2.779M $7.800M $980.0K
YoY Change 183.57% 52.02% -49.14%
% of Gross Profit
Depreciation & Amortization $13.00K $87.00K $32.00K
YoY Change -59.38% -56.72% -44.83%
% of Gross Profit
Operating Expenses $5.265M $14.27M $2.132M
YoY Change 146.95% 40.49% -33.58%
Operating Profit -$14.27M
YoY Change 40.49%
Interest Expense $2.000K $6.000K $0.00
YoY Change -86.36% -100.0%
% of Operating Profit
Other Income/Expense, Net $6.000K
YoY Change -86.36%
Pretax Income -$5.263M -$14.27M -$2.132M
YoY Change 146.86% 41.04% -32.19%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.263M -$14.27M -$2.109M
YoY Change 149.55% 42.06% -32.83%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$398.2K -$0.19 -$99.77K
COMMON SHARES
Basic Shares Outstanding 132.0M 121.9M
Diluted Shares Outstanding 121.9M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.33M $67.33M $6.227M
YoY Change 981.18% 981.18% -58.61%
Cash & Equivalents $67.33M $67.33M $6.227M
Short-Term Investments
Other Short-Term Assets $1.533M $1.533M $1.238M
YoY Change 23.83% 23.83% -10.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00 $469.0K
Total Short-Term Assets $68.86M $68.86M $7.934M
YoY Change 767.89% 767.89% -51.7%
LONG-TERM ASSETS
Property, Plant & Equipment $101.0K $1.484M $174.0K
YoY Change -41.95% 227.59% -77.86%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $23.00K $23.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.507M $1.507M $476.0K
YoY Change 216.6% 216.6% -41.16%
TOTAL ASSETS
Total Short-Term Assets $68.86M $68.86M $7.934M
Total Long-Term Assets $1.507M $1.507M $476.0K
Total Assets $70.37M $70.37M $8.410M
YoY Change 736.68% 736.68% -51.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $524.0K $524.0K $886.0K
YoY Change -40.86% -40.86% -61.73%
Accrued Expenses $1.928M $3.030M $925.0K
YoY Change 108.43% 45.67% -68.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.554M $3.554M $2.966M
YoY Change 19.82% 19.82% -43.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.403M $1.403M $186.0K
YoY Change 654.3% 654.3% -60.68%
Total Long-Term Liabilities $1.403M $1.403M $186.0K
YoY Change 654.3% 654.3% -60.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.554M $3.554M $2.966M
Total Long-Term Liabilities $1.403M $1.403M $186.0K
Total Liabilities $4.957M $4.957M $3.152M
YoY Change 57.27% 1207.92% 9.83%
SHAREHOLDERS EQUITY
Retained Earnings -$271.3M -$248.1M
YoY Change 9.35%
Common Stock $336.7M $240.9M
YoY Change 39.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.41M $65.41M -$4.767M
YoY Change
Total Liabilities & Shareholders Equity $70.37M $70.37M $8.410M
YoY Change 736.68% 736.68% -51.2%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$5.263M -$14.27M -$2.109M
YoY Change 149.55% 42.06% -32.83%
Depreciation, Depletion And Amortization $13.00K $87.00K $32.00K
YoY Change -59.38% -56.72% -44.83%
Cash From Operating Activities -$4.810M -$12.89M -$3.132M
YoY Change 53.58% 5.93% -13.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $14.00K -$5.000K
YoY Change -100.0% 55.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$14.00K -$5.000K
YoY Change -100.0% 55.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $65.96M
YoY Change 1863.68%
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities 0.000 74.00M 3.359M
YoY Change -100.0% 2103.1%
NET CHANGE
Cash From Operating Activities -4.810M -12.89M -3.132M
Cash From Investing Activities 0.000 -14.00K -5.000K
Cash From Financing Activities 0.000 74.00M 3.359M
Net Change In Cash -4.810M 61.10M 222.0K
YoY Change -2266.67% -792.88% -106.16%
FREE CASH FLOW
Cash From Operating Activities -$4.810M -$12.89M -$3.132M
Capital Expenditures $0.00 $14.00K -$5.000K
Free Cash Flow -$4.810M -$12.90M -$3.127M
YoY Change 53.82% 5.97% -13.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121875042
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19011362
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
120000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3973
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-12584
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Ste. 270
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2021 dei Entity Address Country
EntityAddressCountry
MD
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2021 dei City Area Code
CityAreaCode
301
CY2021 dei Local Phone Number
LocalPhoneNumber
417-4364
CY2021 dei Security12b Title
Security12bTitle
Common Stock
CY2021 dei Trading Symbol
TradingSymbol
SYN
CY2021 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
79200000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
158437840
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
Potomac, Maryland
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67325000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6227000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1707000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68858000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
7934000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1383000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
279000
CY2021Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2020Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2021Q4 us-gaap Assets
Assets
70365000
CY2020Q4 us-gaap Assets
Assets
8410000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
886000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
925000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
978000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
868000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
287000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3554000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2966000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1403000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
186000
CY2021Q4 us-gaap Liabilities
Liabilities
4957000
CY2020Q4 us-gaap Liabilities
Liabilities
3152000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
120000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12798000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3973
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
2477000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132044866
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132042538
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29252253
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29249925
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
336560000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
240821000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271284000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248094000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65408000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4767000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-2773000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70365000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8410000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6474000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5029000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7800000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5131000
CY2021 us-gaap Operating Expenses
OperatingExpenses
14274000
CY2020 us-gaap Operating Expenses
OperatingExpenses
10160000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-14274000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10160000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44000
CY2021 us-gaap Profit Loss
ProfitLoss
-14268000
CY2020 us-gaap Profit Loss
ProfitLoss
-10116000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-73000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14267000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10043000
CY2021 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
0
CY2020 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
880000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23189000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12557000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121875042
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19011362
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1057000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
350000
CY2020 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
3359000
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
254000
CY2020 syn Stock Issued During Period Value Of Syn Biomics Stock
StockIssuedDuringPeriodValueOfSynBiomicsStock
178000
CY2020 syn Adjustments To Effect Of Warrant Exercise Price
AdjustmentsToEffectOfWarrantExercisePrice
0
CY2020 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2020 us-gaap Profit Loss
ProfitLoss
-10116000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
416000
CY2021 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
65960000
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24000
CY2021 syn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8042000
CY2021 syn Adjustments To Effect Of Preferred Stock Price
AdjustmentsToEffectOfPreferredStockPrice
0
CY2021 us-gaap Profit Loss
ProfitLoss
-14268000
CY2021 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
0
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2021 us-gaap Profit Loss
ProfitLoss
-14268000
CY2020 us-gaap Profit Loss
ProfitLoss
-10116000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
416000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
350000
CY2021 syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
0
CY2020 syn Subsidiary Stock Issues To Vendor
SubsidiaryStockIssuesToVendor
178000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
201000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-174000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
326000
CY2021 syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
166000
CY2020 syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
141000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-363000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1429000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1004000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-851000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
110000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-67000
CY2021 syn Increase Decrease Lease Liability
IncreaseDecreaseLeaseLiability
-216000
CY2020 syn Increase Decrease Lease Liability
IncreaseDecreaseLeaseLiability
-249000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12890000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12168000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65960000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3359000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8042000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74002000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3359000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
61098000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8818000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6227000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15045000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6227000
CY2021 syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
7402000
CY2020 syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
0
CY2021 syn Return Of Syn Biomics Stock
ReturnOfSynBiomicsStock
2774000
CY2020 syn Return Of Syn Biomics Stock
ReturnOfSynBiomicsStock
0
CY2021 syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1496000
CY2020 syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1380000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1270000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
24000
CY2020 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
254000
CY2021 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
0
CY2020 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
880000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67300000
CY2021 syn Proceeds From Issuance Atm Offering Net Of Issuance Costs
ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts
66000000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1707000
CY2020 syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
0.42
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2021Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.830
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
201000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
868000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
700000
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
500000
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
500000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0112
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0031
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
803000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
639000
CY2021Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
458000
CY2020Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
470000
CY2021Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
272000
CY2020Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
90000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
469000
CY2021Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
0
CY2020Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
39000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
932000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1263000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1089000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
174000
CY2021Q4 syn Accrued Vendor Payments
AccruedVendorPayments
1028000
CY2020Q4 syn Accrued Vendor Payments
AccruedVendorPayments
225000
CY2021Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
696000
CY2020Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
700000
CY2021Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
204000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928000
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
0.33
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
900000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
925000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
886000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
724000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
92000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
144000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
771000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q4 syn Deferred Tax Assets Stock Issued For Milestone Payment
DeferredTaxAssetsStockIssuedForMilestonePayment
236000
CY2020Q4 syn Deferred Tax Assets Stock Issued For Milestone Payment
DeferredTaxAssetsStockIssuedForMilestonePayment
262000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000.0
CY2020Q4 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18714999
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.24
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
714286
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
50.05
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18000713
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
11655747
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.69
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6344966
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 syn Preferred Stock Shares Converted
PreferredStockSharesConverted
1.38
CY2020Q4 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
0.69
CY2021 syn Preferred Stock Shares Converted
PreferredStockSharesConverted
3973
CY2020 syn Preferred Stock Shares Converted
PreferredStockSharesConverted
3665
CY2021Q1 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
1.50
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8996768
CY2021 syn Estimated Fair Value Of Inducement Consideration
EstimatedFairValueOfInducementConsideration
7400000
CY2021 syn Estimated Fair Value Of Inducement Consideration
EstimatedFairValueOfInducementConsideration
7400000
CY2018Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
328000
CY2018Q3 syn Fair Value Of Shares Issued
FairValueOfSharesIssued
285000
CY2020Q4 syn Cost Of Living Adjustments Percentage
CostOfLivingAdjustmentsPercentage
0.625
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
280000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
209000
CY2021Q4 syn Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1462000
CY2020Q4 syn Deferred Tax Assets Stock Issued For Acquisition Of Program
DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
1436000
CY2021Q4 syn Deferred Tax Assets Stock Issued Forlicense Agreement
DeferredTaxAssetsStockIssuedForlicenseAgreement
1363000
CY2020Q4 syn Deferred Tax Assets Stock Issued Forlicense Agreement
DeferredTaxAssetsStockIssuedForlicenseAgreement
1574000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
321000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
309000
CY2021 syn Non Cash Addition Of Right Of Use Assets
NonCashAdditionOfRightOfUseAssets
538000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
247000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
327000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
337000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
347000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
357000
CY2021Q4 syn Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
368000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1983000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
456000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1527000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1403000
CY2017Q4 us-gaap Payments For Fees
PaymentsForFees
4500000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0646
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0818
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0645
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0817
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-3045000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-2124000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-931000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-616000
CY2021 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
32000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
32000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
932000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1221000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3012000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3929000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 syn Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
1504000
CY2020Q4 syn Deferred Tax Assets Stocks Issued For Services
DeferredTaxAssetsStocksIssuedForServices
1428000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
27000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
42000
CY2021Q4 syn Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
4000
CY2020Q4 syn Deferred Tax Assets Tax Deferred Expense Amortizable License Fee
DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
5000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16884000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12540000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21480000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17287000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21480000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17287000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
58300000
CY2021 syn Operating Loss Carryforwards Expire Date
OperatingLossCarryforwardsExpireDate
2037
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21500000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4200000

Files In Submission

Name View Source Status
0001410578-22-000405-index-headers.html Edgar Link pending
0001410578-22-000405-index.html Edgar Link pending
0001410578-22-000405.txt Edgar Link pending
0001410578-22-000405-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20211231.xsd Edgar Link pending
syn-20211231x10k.htm Edgar Link pending
syn-20211231x10k001.jpg Edgar Link pending
syn-20211231x10k002.jpg Edgar Link pending
syn-20211231x10k_htm.xml Edgar Link completed
syn-20211231xex10d32.htm Edgar Link pending
syn-20211231xex10d33.htm Edgar Link pending
syn-20211231xex10d34.htm Edgar Link pending
syn-20211231xex10d34001.jpg Edgar Link pending
syn-20211231xex10d34002.jpg Edgar Link pending
syn-20211231xex10d35.htm Edgar Link pending
syn-20211231xex10d35003.jpg Edgar Link pending
syn-20211231xex10d35004.jpg Edgar Link pending
syn-20211231xex10d4.htm Edgar Link pending
syn-20211231xex21d1.htm Edgar Link pending
syn-20211231xex23d1.htm Edgar Link pending
syn-20211231xex31d1.htm Edgar Link pending
syn-20211231xex32d1.htm Edgar Link pending
syn-20211231xex4d4.htm Edgar Link pending
syn-20211231_cal.xml Edgar Link unprocessable
syn-20211231_def.xml Edgar Link unprocessable
syn-20211231_lab.xml Edgar Link unprocessable
syn-20211231_pre.xml Edgar Link unprocessable